检索结果-南通市图书馆

Risk factors for hepatocellular carcinoma associated with hepatitis C genotype 3 infection:A systematic review

World Journal of Gastrointestinal Oncology 2024年第4期16卷 1596-1612页

作者： Hamzah Z Farooq Michael James Jane Abbott Patrick Oyibo Pip Divall Naheed Choudhry Graham R Foster Blizard Institute Queen Mary University of LondonLondon E12ATUnited Kingdom School of Health and Psychological Sciences University of LondonLondon EC1V 0HBUnited Kingdom University Hospitals of Leicester Library University Hospitals of Leicester NHS TrustLeicester LE39QPUnited Kingdom

BACKGROUND Hepatitis C virus(HCV)is a blood-borne virus which globally affects around 79 million people and is associated with high morbidity and *** infection leads to cirrhosis in a large proportion of patients and often causes hepatocellular carcinoma(HCC)in people with *** the 6 HCV genotypes(G1-G6),genotype-3 accounts for 17.9%of *** genotype-3 responds least well to directly-acting antivirals and patients with genotype-3 infection are at increased risk of HCC even if they do not have *** To systematically review and critically appraise all risk factors for HCC secondary to HCV-G3 in all ***,we studied possible risk factors for HCC due to HCV-G3 in the literature from 1946 to *** This systematic review aimed to synthesise existing and published studies of risk factors for HCC secondary to HCV genotype-3 and evaluate their strengths and *** searched Web of Science,Medline,EMBASE,and CENTRAL for publications reporting risk factors for HCC due to HCV genotype-3 in all settings,*** Four thousand one hundred and forty-four records were identified from the four databases with 260 records removed as *** thousand eight hundred and eighty-four records were screened with 3514 *** hundred and seventy-one full-texts were assessed for eligibility with seven studies included for *** the seven studies,three studies were retrospective case-control trials,two retrospective cohort studies,one a prospective cohort study and one a cross-sectional study *** were based in hospital settings with four in Pakistan,two in South Korea and one in the United *** total number of participants were 9621 of which 167 developed HCC(1.7%).All seven studies found cirrhosis to be a risk factor for HCC secondary to HCV genotype-3 followed by higher age(five-studies),with two studies each showing male sex,high alpha feto-protein,directly-acting antivirals trea

关键词： Hepatocellular carcinoma Hepatitis C genotype 3 Systematic review Blood-borne viruses Liver cancer

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

genotype 3-hepatitis C virus’last line of defense

引用

World Journal of Gastroenterology 2021年第11期27卷 1006-1021页

作者： Dorota Zarębska-Michaluk Department of Infectious Diseases Jan Kochanowski UniversityKielce 25-369ŚwiętokrzyskiePoland

Chronic infection with hepatitis C virus(HCV)is one of the leading causes of liver disease globally,affecting approximately 71 million *** majority of them are infected with genotype(GT)1 but infections with GT3 are second in *** many years,GT3 was considered to be less pathogenic compared to other GTs in the HCV family due to its favorable response to interferon(IFN)-based ***,the growing evidence of a higher rate of steatosis,more rapid progression of liver fibrosis,and lower efficacy of antiviral treatment compared to infection with other HCV GTs has changed this *** review presents the specifics of the course of GT3 infection and the development of therapeutic options for GT3-infected patients in the era of direct-acting antivirals(DAA).The way from a standard of care therapy with pegylated IFNalpha(pegIFNα)and ribavirin(RBV)through a triple combination of pegIFNα+RBV and DAA to the highly potent IFN-free pangenotypic DAA regimens is discussed along with some treatment options which appeared to be dead *** the implementation of highly effective pangenotypic regimens is the most recent stage of revolution in the treatment of GT3 infection,there is still room for improvement,especially in patients with liver cirrhosis and those who fail to respond to DAA therapies,particularly those containing inhibitors of HCV nonstructural protein 5A.

关键词： Hepatitis C virus genotype 3 Antiviral treatment Interferon Direct-acting antivirals Pangenotypic

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Direct-acting Antiviral Regimens for Patients with Chronic Infection of Hepatitis C Virus genotype 3 in China

引用

Journal of Clinical and Translational Hepatology 2021年第3期9卷 419-427页

作者： Xiaozhong Wang Lai Wei Department of Hepatology Affiliated Hospital of Traditional Chinese Medicine of Xinjiang Medical UniversityUrumqiXinjiangChina Hepatopancreatobiliary Center Beijing Tsinghua Changgung HospitalSchool of Clinical MedicineTsinghua UniversityBeijingChina

Hepatitis C virus(HCV)genotype(GT)3 infection is associated with a more rapid hepatic disease progression than the other ***,early HCV clearance slows down the disease progression and is important for improving prognosis in GT3-infected ***,compared with other genotypes,GT3 is difficult-to-treat with direct-acting antivirals,especially in the presence of *** guidelines recommend several regimens which have been proven to be effective in GT3-infected patients from the Western world(North America,Europe,and Oceania).In China,GT3 infection comprises 8.7–11.7%of the 10 million patients infected with HCV and has strikingly different characteristics from that in Western *** the Western countries,where GT3a is the predominant subtype,GT3a and 3b each affect roughly half of Chinese GT3-infected patients,with 94–96%of the GT3b-infected patients carrying A30K+L31M double NS5A resistance-associated *** 3 clinical trials including GT3b-infected patients have suggested that GT3b infection is difficult to cure,making the regimen choice for GT3b-infected patients an urgent clinical gap to be *** review includes discussions on the epidemiology of HCV GT3 in China,recommendations from guidelines,and clinical data from both Western countries and *** aim is to provide knowledge that will elucidate the challenges in treating Chinese GT3-infected patients and propose potential solutions and future research directions.

关键词： Cirrhosis Direct-acting antivirals Hepatitis C genotype 3 Resistance-associated substitutions

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：